Archives of Disease in Childhood Fetal & Neonatal · 2017 · 61 citations · 37 references
MedicineChild HealthPediatricsNeonatal HealthNeonatologyPatient SafetyCare Of Premature InfantsCatheter-associated Infection PreventionInfant SafetyInfection In Preterm BirthNeonatal Intensive CareNeonatal SafetyCatheter-related Safety In NeonatesInfant Infection PreventionInsertion Site PreparationNeonatal Antimicrobial ProphylaxisNeonatal Thyroid DysfunctionOutcome MeasuresPrimary Outcome AnalysisRandomized Clinical Trials
OBJECTIVE: To determine whether 2% chlorhexidine gluconate-70% isopropyl alcohol (CHX-IA) is superior to 10% aqueous povidone-iodine (PI) in preventing catheter-related blood stream infection (CR-BSI) when used to clean insertion sites before placing central venous catheters (CVCs) in preterm infants. DESIGN: Randomised controlled trial. SETTING: Two neonatal intensive care units (NICUs). PATIENTS: Infants <31 weeks' gestation who had a CVC inserted. INTERVENTIONS: Insertion site was cleaned with CHX-IA or PI. Caregivers were not masked to group assignment. MAIN OUTCOME MEASURES: Primary outcome was CR-BSI determined by one microbiologist who was masked to group assignment. Secondary outcomes included skin reactions to study solution and thyroid dysfunction. RESULTS: We enrolled 304 infants (CHX-IA 148 vs PI 156) in whom 815 CVCs (CHX-IA 384 vs PI 431) were inserted and remained in situ for 3078 (CHX-IA 1465 vs PI 1613) days. We found no differences between the groups in the proportion of infants with CR-BSI (CHX-IA 7% vs PI 5%, p=0.631), the proportion of CVCs complicated by CR-BSI or the rate of CR-BSI per 1000 catheter days. Skin reaction rates were low (<1% CVC insertion episodes) and not different between the groups. More infants in the PI group had raised thyroid-stimulating hormone levels and were treated with thyroxine (CHX-IA 0% vs PI 5%, p=0.003). CONCLUSIONS: We did not find a difference in the rate of CR-BSI between preterm infants treated with CHX-IA and PI, and more infants treated with PI had thyroid dysfunction. However, our study was not adequately powered to detect a difference in our primary outcome and a larger trial is required to confirm our findings. TRIAL REGISTRATION: This study was registered with the EU clinical trials register before the first patient was enrolled (Eudract 2011-002962-19). (https://www.clinicaltrialsregister.eu).
37
Teresa Horan, Mary Andrus, Margaret A. Dudeck · American Journal of Infection Control · 2008 · 6.6K citations
Public Health, Infectious Disease Control, Infectious Diseases +16
Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network
Barbara J. Stoll, Nellie I. Hansen, Edward F. Bell et al. · PEDIATRICS · 2010 · 2.7K citations · Full text